Ixekizumab (I-DIT / IL-17A blockade)
What it is
The IL-17A antibody ixekizumab is being tested for beta-cell preservation after T1D diagnosis. I-DIT is active but no longer recruiting, with no results posted.
Editorial review: . What was checked and what remains uncertain.
Latest dated source in the citation list: 2026-04-27. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Beta-cell preservation: The randomized I-DIT study has no posted C-peptide efficacy results.[1]
- Important harms and treatment burden
- Safety: The US label warns about serious infections, hypersensitivity, eczema and inflammatory bowel disease; T1D-specific risk-benefit is unestablished.[2]
- Approval and country access
- The IL-17A antibody ixekizumab is being tested for beta-cell preservation after T1D diagnosis. I-DIT is active but no longer recruiting, with no results posted.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: A lasting T1D benefit has not been demonstrated; the protocol tests 12 months of treatment.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 12 × 30 + 10 × 20 + 35 × 20 + 25 × 10 + 25 × 20 = 2010; divide by total weight 100. Unrounded weighted result: 20.1.
A lasting T1D benefit has not been demonstrated; the protocol tests 12 months of treatment.[1]
The US label warns about serious infections, hypersensitivity, eczema and inflammatory bowel disease; T1D-specific risk-benefit is unestablished.[2]
I-DIT selected adults 18–45 within 100 days of first insulin, with autoantibodies and residual C-peptide.[1]
Phase 2 is active, not recruiting; its 127-person enrolment figure remains an estimate.[1]
The full picture
Research question and current position
I-DIT tests whether IL-17A blockade can preserve insulin production in adults with recent-onset autoimmune T1D. The proposed mechanism is a hypothesis; it is not proof that psoriasis treatment works in diabetes. The registry lists a randomized Phase 2 trial, active but not recruiting, and estimated primary completion in February 2027. No results are posted.1
Approval and harms
The US Taltz label covers psoriasis and several inflammatory arthritides, not T1D. Its warnings include serious infections, tuberculosis assessment, severe allergic reactions, eczema and inflammatory bowel disease; live vaccines should be avoided during treatment. Those known risks matter even though the diabetes benefit remains unproven. Approval for another condition does not establish T1D access or suitability.2
Sources
- [1]NCT04589325 — study record · registry · 2026-04-27 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.
- [2]Taltz (ixekizumab) US prescribing information, revised January 2026 · regulatory — Approved indications and known drug risks; not evidence of T1D efficacy.